Disitamab vedotin is an anti-HER2 antibody-drug conjugate (ADC). It is mainly indicated for patients with advanced solid tumors confirmed to have HER2‑positive expression by pathological or molecular testing, including specific indications such as gastric cancer and urothelial carcinoma. Its use must strictly follow medical orders, with a comprehensive judgment based on the patient’s condition and test results.
Indicated Populations and Clinical Scenarios
1. HER2‑Positive Advanced Gastric Cancer Patients
It is indicated for patients with HER2‑positive locally advanced or metastatic gastric cancer who have received at least two lines of systemic chemotherapy (including taxanes or platinum‑based regimens).
HER2 positivity must be confirmed by immunohistochemistry (IHC 2+/3+) or fluorescence in situ hybridization (FISH).
2. HER2‑Positive Urothelial Carcinoma Patients
It is used for the treatment of locally advanced or metastatic urothelial carcinoma in patients with HER2 overexpression (IHC 2+/3+) who:
have experienced disease progression after prior platinum‑based chemotherapy; or
are ineligible for platinum‑based chemotherapy.
3. Exploratory Treatment of Other HER2‑Expressing Solid Tumors
Clinical studies are ongoing for HER2‑positive solid tumors including breast cancer and biliary tract cancer. Eligibility must be evaluated by a physician on an individual basis.
Precautions for Use
Prescription drug requirement
Must be prescribed by a specialized oncologist based on the patient’s condition; self‑medication is prohibited.
Pre‑treatment testing
HER2 expression status must be confirmed by pathological biopsy to avoid inappropriate use.
Adverse event monitoring
May cause adverse reactions including interstitial lung disease and hepatotoxicity. Vital signs and laboratory tests must be closely monitored during treatment.
Contraindicated patients
Contraindicated in individuals with hypersensitivity to any ingredient of the drug, or in patients with severe hepatic insufficiency. The risks and benefits must be fully evaluated in pregnant or lactating women.
Medical Guidance
If you meet the above indications and testing confirms HER2 positivity, please bring complete medical records to the Department of Medical Oncology or relevant subspecialty for consultation. A physician will develop an individualized treatment plan.
During treatment, regular imaging and blood tests are required to dynamically assess efficacy and safety.
